Member Info for Laura2022

Stockraiser

Here are some thoughts

Worth also looking at Trench123, Burt777 (TR1, kinghomerj

Comparisons(basic and nead to adjust for cash /losses for each ) in bio tech sphere as of Sept 2025

Below is a post on a similar bio tech service company to PYC

AbSci is valued at $450m on $4m annual revenues (x 100)

By that token XXX should be £100m cap or around 80-90p a share now

I think eventually XXX could be a £1billion pound company so £10 a share not out the question. ...

APTA £35mln cap and £1.2mln full year revs( = x 30 annual rev)

FAB £17 mln and £1.96mln full year ( x 9)

PYC £1.4mln and £0.85mln full year ( x less than 2 )

IMM £20mln cap (pre revenue)

Alot of catching up

Clarify

NT £5K

3 x 1mln buys now

Good start

Spreadex went to 6% and presumably sold them to a buyer?

01-Sep-25 15:38:20 0.4999 1,340,670 Unknown* 6,702 O

01-Sep-25 15:35:18 0.5222 1,971,947 Unknown* 10.30k

Is that a buy/sell or the warrants GLR .?

The one for 3mln is difficult as it jumped to 0.44/45 to buy after that time

But hard to tell, 50/50

01-Sep-25 15:38:20 0.4999 1,340,670 Unknown* 6,702 O

01-Sep-25 15:35:18 0.5222 1,971,947 Unknown* 10.30k

£1.4mln cap and valued less than x 2 earnings versus peers who are valued x 10-30

7th August : follow on contract with leader in A.i medicine. Phase 1 trial , £38k over 2 mths

16th July - new contract with partner Numab

14th July - Trading statement

ahead of expectations for FY25. When compared to the year ended 30 June 2024 (FY24), these unaudited numbers would represent an increase in Total Income of approximately 46%

10th July : integration of PYC platform into global personalosed medical provoder DoseMeRx

1st July - new contract and a Master Service Agreement for deeper relationship

16th June x 2 biostatistics contracts (first ones from new division)

29th May RNSPhysiomics Awarded Contract Extension

9th May RNSContract Award with New UK Client

17th Apr Physiomics Awarded New Contract

16th Apr RNS-R Publication of Peer Reviewed Article

15th Apr new contract

17th Mar RNS Contract Award with new client

Stockraiser

Possibly ( worth reading the last 3mths updates )

Kalimera

Some large moves across bio tech last few weeks

APTA x 6

HEMO x 4

FAB x 3

IMM x 4

A must read given today's volume

KingHomerJ

Posted in: PYC

Posts: 1,805

Price: 0.425

No Opinion

DosemeRX Tool / Current State of Play13 Aug 2025 13:21

At current cost base, a sustained revenue run rate of £1.2–£1.3M/year likely delivers profitability.

The G-CSF tool alone, could cover the gap significantly within the first year of commercial launch.

This makes the tool approval/commercialisation a profit inflection point.

Doseme software is already highly integrated into some of the biggest platforms on earth

Doseme already supports (Epic, Oracle Health/Cerner, Wolters Kluwer Sentri7, Inovalon’s VigiLanz). all multi multi billion £ companies.

The intergration is commercially EASY as we can Offer a tiered add-on to existing DoseMeRx contracts (per-oncology-patient census or per-bed), plus a research-use pathway for rapid onboarding—matching what Physiomics already announced (initial research availability to selected DoseMe clients).

G-CSF dosing tool via DoseMeRx could contribute £2.81M (Conservative) on soft launch and initial uptake in 2026 alone, which would push the company well into profitability.

Puts the funding lies to bed

accredited, in-demand, and built to scale - announces that Chris Brooks, Managing Director of the Company, acquired, in aggregate, 28,292 ordinary shares of £0.0025 each in capital of the Company ("Ordinary Shares") at an average price of 15.4 pence per share in August 2025.

96kb

Dowgate had 6mln as of 12th Aug

They're gone now I think

PYC could be next bio tech too

Certainly crazy to be only £1.3mln :)

Osb/vip

Bio techs on a surge

Central C

Its simply a question of people becoming aware of REE

I've personally been here 6mths but not as long as others

Added another bio tech but very different as drug development company as opposed to service provoder

APTA £35mln cap and £1.2mln full year revs( = x 30 annual rev)

FAB £17 mln and £1.96mln full year ( x 9)

PYC £1.4mln and £0.85mln full year ( x less than 2 )

IMM £11mln cap (pre revenue)

Alot of catching up

Just found out USA markets not open today ?

Seem to be having a renaissance this last month or so

STX ( I hold ) , VAL FAB APTA